



Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Private Company Conference Series

March 23, 2015

Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, today announced that Michael D. Taylor, Ph.D., Deciphera's President and Chief Executive Officer, will present a corporate update at the JMP Securities Life Sciences Private Company Conference Series on Friday, March 27, 2015 at 11:30 a.m. ET in New York.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals seeks to improve treatment for patients with cancer by designing kinase inhibitor therapies that target the hallmarks of cancer biology. We specifically design our small molecule compounds to simultaneously block multiple cancer signaling mechanisms in the tumor cell and the tumor microenvironment to prevent growth and spread. Deciphera's unique approach represents an important advance over current therapies in the durability of kinase inhibition and resiliency to genetic mutations to provide greater benefit across a range of cancers. Deciphera's business strategy is to advance its drug candidates for genetically-defined cancers and cancers that target the tumor microenvironment through both proprietary and partnered programs.

Deciphera's internal product pipeline includes altiratinib, a MET/TIE2/VEGFR2/TRK kinase inhibitor currently in Phase 1 clinical development, a pan-KIT inhibitor

(DCC-2618) currently in preclinical development, and rebastinib, a TIE2/VEGFR1 kinase inhibitor currently in Phase 1 clinical development. A specific FMS inhibitor, DCC-3014, which was designed to block the actions of pro-tumoral macrophages in the tumor microenvironment, is in preclinical development. In addition, we developed a pan-RAF inhibitor (LY-3009120) in collaboration with our partner Eli Lilly that is currently in Phase 1.

Contacts:

Michael D. Taylor, Ph.D., Deciphera Pharmaceuticals

mtaylor@deciphera.com

617-460-7205

Media:

Gina Nugent, The Yates Network

gina@theyatesnetwork.com

617-460-3579